Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Veriheal

NOVEMBER 18, 2022

Texas’ medical cannabis program is in the midst of a massive spike in patient registrations. According to the Texas Department of Public Safety Chief Wayne Muller, the state has averaged a 10% month-over-month increase in medical cannabis patients over the last 18 months. Let us know in the comments!

Edibles 97

Edibles Hemp Epilepsy Programs 97

Cannabis Law Report

JANUARY 31, 2019

January 31, 2019. Portland, OR — Today the Oregon Liquor Control Commission provided the Oregon Legislative Assembly with the 2019 Recreational Marijuana Supply and Demand Legislative Report required by ORS 475B.548. 2019 Recreational Marijuana Supply and Demand Legislative Report. Here’s the statement in full.

Legislation 61

Legislation Recreational Marijuana Policy 61

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. 14th at 11:00 a.m. PT (2:00 p.m.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

SpeedWeed

MARCH 6, 2021

Public safety at issue. Proponents of these THC caps—who are often the same politicians who stood against legalization and lost—contend that limiting THC levels will increase public safety. The 2019 EVALI/VAPI health crisis was caused by illegal-market vape cartridge manufacturers introducing toxic thinners into their products. .

THC 52

THC Patients Law Chronic Pain 52

Cannabis Law Report

JUNE 17, 2022

status as a medical cannabis program patient,” or. The bill’s protections do not extend to employees whose “position is designated as safety sensitive.” Both the use of cannabis for adults and for patients is permitted in the District of Columbia.

Safety 52

Safety Legislation Policy Cannabis 52

Veriheal

AUGUST 22, 2022

Based on the details of a June 21 press release, the trials—which are taking place in Johannesburg—are the first ethically approved studies exploring the suitability and safety of using cannabis as a substitute for opioid pain relievers. . According to the 2019 National Survey on Drug Use and Health , an estimated 10.1 milligrams.

Clinical Trials 113

Clinical Trials Chronic Pain Hydroponic Strains 113

Cannabis Law Report

AUGUST 16, 2021

It is also a tool used to “determine the nature and scope of child abuse and neglect” and compare Arizona data to national trends, regardless of whether that neglect or abuse arose from the lawful or unlawful use of substances, a mental illness or incapacity, or simply an inability to properly care for a child.

Safety 116

Safety Patients Cannabis Law 116

The Blunt Truth

AUGUST 13, 2019

In March of 2019, the FDA established a Working Group to determine the possible legislative pathways to regulate CBD. On May 31, 2019, the FDA’s Working Group held a public hearing for stakeholders to share their experiences and challenges with CBD products, including information and views related to product safety.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Cannabis Law Report

JUNE 5, 2019

30 May 2019. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Press Release: Thailand Government Pharmaceutical Organization.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients. Recent data suggest the US science knowledge is about the global average.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Marijuana Lawyer Blog

FEBRUARY 9, 2020

Since its passing in 2016, Prop 64 has earmarked its entire cannabis industry tax revenue, minus regulatory costs, to supporting public health, repairing the environment, and bettering public safety. Marijuana Tax Revenue Expenditures in California (Fiscal Year 2019-2020). 20 percent to public safety initiatives.

Marijuana 64

Marijuana Safety Programs Dispensary 64

Cannabis Law Report

MARCH 19, 2020

FDA’s announcement comes on the heels of an active 2019, during which both FDA and the FTC issued warning letters to marketers of CBD products 1 and the plaintiffs’ bar began to actively file class-action lawsuits against marketers of CBD products under state law. FDA submitted this report last week, as is discussed below.

CBD 45

CBD Research and Development Seed-To-Sale Data 45

Cannabis Law Report

JANUARY 23, 2022

Multivariate analysis of overall survival and nonrelapse mortality (NRM) data has shown GVHD likelihood can be impacted by age, prior acute GVHD, time from transplantation to cGVHD, donor type, disease status at transplantation, GVHD prophylaxis, gender mismatch, serum bilirubin, Karnofsky score, and platelet count (Arora et al. Implications.

Research and Development 52

Research and Development Wellness and Beauty Patients CBD 52

Cannabis Law Report

OCTOBER 21, 2021

adults shows broad support for securely labeling cannabis products to verify their legitimacy and safety in the marketplace. Ensuring the safety of cannabis products is top of mind for Americans.

Safety 52

Safety Research and Development Compliance Compliance 52

The Cannigma

AUGUST 24, 2021

Google announced in May, 2019 that they had updated their policy section of the Google to ban apps “that facilitate the sale of marijuana or maijruan products, regardless of legality.” As co-founder Otha Smith said, “through data, we aim to empower not only cannabis consumers, but the entire industry.”. Learn More.

Seed-To-Sale 111

Seed-To-Sale Research and Development Data Strains 111

The Cannigma

AUGUST 31, 2021

The researchers stated that these knowledge gaps must be addressed and that “clinical trial data about how medical cannabis improves patient quality of life domains is desperately needed as this information can impact clinical decision-making.”. People want to trust their doctors, but doctors need knowledge” (Shutterstock).

Education 101

Education Clinical Trials Medicine Policy 101

WeedAdvisor

SEPTEMBER 26, 2019

Medical patients already enjoy some major advantages over the upcoming recreational market, which is why it is bizarre that, historically, recreational marijuana takes a huge chunk out of medical sales. One notable change is the sheer number of patients that enrolled in the past year. In August, 2018, 44,000 registered patients.

Recreational 45

Recreational Patients Programs History 45

Cannabis Law Report

NOVEMBER 6, 2019

5, 2019) — ValidCare, the hemp industry’s leading market intelligence and consumer research platform, and the University of Kentucky Research Foundation (UKRF) have announced they have entered into a services agreement to advance the research of hemp-derived products. LEXINGTON, Ky. About ValidCare.

Hemp 45

Hemp Data Access Education 45

Cannabis Law Report

FEBRUARY 20, 2020

The Long Beach Collective Association (“ LBCA “), cannabis business owners, policy advocates, patients, consumers, and city officials came together to support the city’s legal cannabis business community to lower taxes. MRR report. Lowering the tax rate will also help keep more jobs in Long Beach because it helps keep prices competitive.

Collective 59

Collective Policy Cannabis Cultivation 59

Cannabis Law Report

JULY 11, 2019

Board Certification – Effective May 7, 2019, SB 162 removed the requirement for physicians issuing recommendations to patients for medical marijuana to be board certified. OMMA is currently evaluating implementation timelines for this data infrastructure. This change aligns with language in HB 2612.

Legislation 55

Legislation Programs Seed-To-Sale Marijuana 55

SpeedWeed

MARCH 11, 2021

A new study recently published in the Journal of Adolescent Health collected data on 14,798 adolescents aged 12 to 17 who vaped weed or tobacco between December 2016 and January 2018. ” The study highlights concerns over the safety of cannabis vaping, but as a whole, it raises more questions than it answers.

Vaping 52

Vaping Sleep History Collective 52

Cannabis Law Report

JULY 30, 2019

Industry leaders have much to say, as well, as reported in Ruben Espinosa’s June 13, 2019 piece for Cannabis Business Executive , concerning whether or not the federal courts force cannabis out of the prohibitive Schedule I Class? ” These patients then have access to purchasing the substance from a regulated state dispensary.

Marijuana 40

Marijuana Education Patients Research and Development 40

Cannabis Law Report

APRIL 22, 2019

The FDA is however finally allowing the public to weigh in, with the announcement of a Public Hearing to take place on May 31, 2019. What’s more, is that the Agency is allowing submission of public comment until July 2, 2019 and seems to earnestly want feedback from the hemp industry. April 20, 2019.

Hemp 56

Hemp Compliance Compliance CBD 56

Cannabis Law Report

FEBRUARY 17, 2022

WORCESTER – The Cannabis Control Commission (Commission) is alerting patients and consumers to its quarantine order (Order), issued October 18, 2021, mandating that ACK Natural, LLC, a colocated medical- and adult-use licensee, recall all products with unverifiable mycotoxin test results sold to its consumers and patients.

Marijuana 52

Marijuana Seed-To-Sale Safety Patients 52

Greenspoon Marder Cannabis Law Group Blog

JULY 18, 2019

In New Jersey, there are nearly 50,000 registered medical marijuana patients and only six Alternative Treatment Centers (ATCs) currently operating. The Garden State’s Governor, Phil Murphy, signed the Jake Honig Compassionate Use Medical Marijuana Act (CUMMA) on July 2, 2019. authorizes home delivery to patients. Criterion 2.

Law 40

Law Marijuana Education Safety 40

The Cannigma

DECEMBER 20, 2021

Skin disorders such as dermatitis, psoriasis and acne can all greatly affect a patient’s quality of life. In 2019, a small study tested CBD ointment for its therapeutic potential within the skin, including patients with acne, dermatitis, and psoriasis.

Terpenes 133

Terpenes Cannabinoids Topical Research and Development 133

Cannabis Law Report

AUGUST 4, 2021

We thus provide comparison with the pre-pandemic period of H1 2019 as an additional data point. Core Business organic growth was 16% in H1 2021 vs. H1 2019, and close to 13% vs. H1 2019 corrected for the EUR 62m estimated missing revenues from the cyber-attack of 2 June 2019. for the three historic TIC leaders.

Business 105

Business Research and Development Environment Food 105

Cannabis Law Report

JULY 20, 2019

In New Jersey, there are nearly 50,000 registered medical marijuana patients and only six Alternative Treatment Centers (ATCs) currently operating. The Garden State’s Governor, Phil Murphy, signed the Jake Honig Compassionate Use Medical Marijuana Act (CUMMA) on July 2, 2019. authorizes home delivery to patients.

Law 40

Law Marijuana Education Cultivation 40

Cannabis Law Report

SEPTEMBER 25, 2019

She added, “Here, we are faced with the challenge of balancing public safety concerns like robberies, which the use of body cameras are intended to deter, with individual privacy.”. FOR IMMEDIATE RELEASE: September 24, 2019. We depend on a good relationship with law enforcement. Cannabis Control Commission Official Announcement.

Marijuana 40

Marijuana Safety Programs Retail 40

Cannabis Law Report

MAY 29, 2022

In May 2019, Denver became the first city to decriminalize psilocybin, followed by Oakland, CA, Washington, D.C., In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] 5, 2019), [link]. [9] and Seattle, among other municipalities. Recent Regulatory Developments. 20, 2020), [link].

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

MARCH 30, 2020

Employers must attempt to balance public health concerns, compliance with emergency government orders, employee safety, consumer demand, and financial reality. 33 states currently have some type of medical marijuana program with an estimated 3 million total patients across the country. Authored By: Patrick McKnight.

Marijuana 59

Marijuana Dispensary Patients Business 59

Cannabis Law Report

JUNE 26, 2019

Ultimately it will be the decision of the medical consultant, in consultation with their patient, to prescribe a particular treatment, including a cannabis-based treatment, for a patient under their care. Patients with a specified medical condition should see their medical consultant for advice.

Medicine 55

Medicine Access Business Legislation 55

Ezra Parzybok

FEBRUARY 12, 2020

Yet the challenges and risks of treating PPD patients with these medications seem to leave women skeptical about accepting the solution. A study published in 2019 in the Permanente Journal shows improvement in the condition among anxious sleeper after usage of CBD. 79% of the users showed decreased anxiety levels, and 66.7%

Research and Development 52

Research and Development Sleep Treatment CBD 52

Cannabis Law Report

JANUARY 9, 2022

In the 2019 and 2020 fiscal years, state officials reported that revenue from the 37% cannabis retail tax outpaced alcohol tax revenue, despite the fact that many more adults consume alcohol than cannabis. The state’s medical patients (about 0.5% The city of Denver, for example, applies an additional 5.5% million as of November 2021.

Collective 52

Collective Policy Retail Programs 52

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JULY 23, 2019

In April 2019 Thurston filed a class action lawsuit in California against Koi CBD, suing it for violations of California State Unfair Competition and Consumer Legal Remedies Laws and the Pennsylvania Unfair Trade Practices and Consumer Protection Law. She lost her job as a result. a playground, recreation centre, library or public park.

Law 40

Law Clinical Trials CBD Edibles 40